GRP78 Activity Moderation as a Therapeutic Treatment against Obesity

Int J Environ Res Public Health. 2022 Nov 30;19(23):15965. doi: 10.3390/ijerph192315965.

Abstract

Glucose-regulated protein 78 (GRP78), a molecular chaperone, is overexpressed in patients suffering from obesity, fatty liver, hyperlipidemia and diabetes. GRP78, therefore, can be not only a biomarker to predict the progression and prognosis of obesity and metabolic diseases but also a potential therapeutic target for anti-obesity treatment. In this paper, GRP78 inhibitors targeting its ATPase domain have been reviewed. Small molecules and proteins that directly bind GRP78 have been described. Putative mechanisms of GRP78 in regulating lipid metabolism were also summarized so as to investigate the role of GRP78 in obesity and other related diseases and provide a theoretical basis for the development and design of anti-obesity drugs targeting GRP78.

Keywords: GRP78; action mechanism; metabolic disorder; molecular target; obese.

Publication types

  • Review

MeSH terms

  • Endoplasmic Reticulum Chaperone BiP* / antagonists & inhibitors
  • Humans
  • Obesity* / drug therapy
  • Obesity* / metabolism

Substances

  • Endoplasmic Reticulum Chaperone BiP
  • HSPA5 protein, human